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INTRODUCTION
The emergence of different cell types during embryogenesis
depends on signals, usually from adjacent tissues, leading to
the expression of genes that determine the differentiation
programme the cell will enter. Activation of a regulatory
cascade culminates in the acquisition of a tissue-specific
phenotype. Skeletal myogenesis conforms to this model. In the
mouse embryo, Myf5 is the myogenic determination factor that
is responsible for directing cells into the skeletal muscle
programme (Braun et al., 1992; Tajbakhsh et al., 1996b). In
keeping with this role, Myf5 is capable of remodelling the
chromatin of muscle genes, rendering them accessible to
transcriptional activation (Bergstrom and Tapscott, 2001;
Gerber et al., 1997). At later stages of development, the
expression of MyoD can also activate the myogenic cascade.
The double null mutation of Myf5 and MyoD prevents the
formation of skeletal muscle precursor cells (Rudnicki et al.,
1993). However Myf5, together with Pax3, lies upstream of
MyoD (Myod1 – Mouse Genome Informatics) in the genetic
hierarchy that regulates myogenesis (Tajbakhsh et al., 1997).
Mrf4 (Myf6 – Mouse Genome Informatics) and myogenin, the
other two members of the family of basic-helix-loop-helix
transcription factors to which MyoD and Myf5 belong, are
implicated in muscle cell differentiation in the embryo.
Myogenin is directly involved in the transcriptional activation
of muscle genes and in its absence many skeletal muscles are
compromised (Venuti et al., 1995), whereas Mrf4 appears to
play this role for the differentiation of the myotome, the earliest
muscle mass to form in the embryo (Buckingham, 1994;
Nabeshima et al., 1993). MyoD can also act as a differentiation
factor, as evidenced by the phenotype of the MyoD/Mrf4
double mutant where myoblasts are present but fail to
differentiate (Rawls et al., 1998). 
During embryogenesis, the spatiotemporal expression of
Myf5 marks skeletal muscle precursor cells and sites of
myogenesis (see Tajbakhsh and Buckingham, 2000). In newly
formed somites, it is expressed before the other myogenic
factors, in the epaxial part of the dermomyotome, adjacent to
the neural tube. This is the first source of muscle precursor
cells, which involute and migrate from this epithelium to form
the first differentiated skeletal muscle, the myotome. The
hypaxial extremity of the dermomyotome and later somitic bud
is also a source of muscle precursors, which express Myf5 and
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Myf5 is the first myogenic regulatory factor to be expressed
in the mouse embryo and it determines the entry of cells
into the skeletal muscle programme. A region situated
between –58 kb and –48 kb from the gene directs Myf5
transcription at sites where muscles will form. We now
show that this region consists of a number of distinct
regulatory elements that specifically target sites of
myogenesis in the somite, limbs and hypoglossal cord, and
also sites of Myf5 transcription in the central nervous
system. Deletion of these sequences in the context of the
locus shows that elements within the region are essential,
and also reveals the combinatorial complexity of the
transcriptional regulation of Myf5. Both within the –58 kb
to –48 kb region and elsewhere in the locus, multiple
sequences are present that direct transcription in
subdomains of a single site during development, thus
revealing distinct phases of myogenesis when
subpopulations of progenitor cells enter the programme of
skeletal muscle differentiation.
Key words: Myf5, Mouse embryo, Myogenesis, Transcriptional
regulation, BACs, Myotome, Limb, CNS
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form the hypaxial myotome, the origin of intercostal and body
wall muscles (Christ et al., 1983). This part of the
dermomyotome, in somites at the appropriate axial level, also
gives rise to cells which migrate to other sites of myogenesis,
to the limb buds or, via the hypoglossal chord (Mackenzie et
al., 1998; Noden, 1983), to the pharynx, tongue and probably
also diaphragm (Tremblay et al., 1998). Cells that migrate to
the limb do not express Myf5 until they reach their destination
(Tajbakhsh and Buckingham, 1994). Myf5-positive cells are
already present in the hypoglossal cord where, in contrast to
the limb progenitors, they do not migrate as separate
mesenchymal cells, but rather as a coherent cell mass (Noden,
1983). Myf5 is also expressed in the branchial arches in cells
derived from anterior paraxial mesoderm which will contribute
to the formation of facial muscles. An unexpected site of Myf5
expression is in neurones, in prosomeres p1 and p4 of the brain
(Tajbakhsh and Buckingham, 1995) and in a ventral domain of
the neural tube (Tajbakhsh et al., 1994). The Myf5 protein does
not accumulate in the central nervous system and there is no
detectable neuronal perturbation in the Myf5 mutant embryos
(Daubas et al., 2000).
The molecular mechanisms that lead to Myf5 activation at
these multiple sites in the embryo are largely unknown. Signals
from the axial structures, neural tube and notochord, and from
surface ectoderm are required for the initiation of myogenesis
in the somite in the mouse (Summerbell and Rigby, 2000;
Tajbakhsh and Buckingham, 2000), as in the avian embryo
(Christ and Ordahl, 1995). Sonic hedgehog from the notochord
and floor plate of the neural tube, as well as Wnt proteins
produced by the dorsal neural tube and surface ectoderm, have
been implicated in Myf5 activation, which is particularly
responsive to b -catenin-dependent Wnt1 signalling, as shown
in mouse embryo explants of presomitic mesoderm or
immature somites (Borycki et al., 1999; Tajbakhsh et al.,
1998). Expression of Myf5 in explants from the region of the
brain where the gene is transcribed also responds in this way
to Wnt1, leading to the suggestion that this may reflect
misfiring of a regulatory element that normally directs Myf5
transcription in the somite, in response to the Wnt1 signal
(Daubas et al., 2000).
The multiple regulatory elements that direct the complete
spatiotemporal expression pattern of Myf5 in the embryo have
been mapped within 145 kb of genomic DNA by YAC
(Hadchouel et al., 2000) and BAC (Carvajal et al., 2001a)
transgenic analysis. Another gene, which encodes the
myogenic regulatory factor Mrf4, lies 7 kb 5 ¢ of the Myf5 gene
(Braun et al., 1990; Miner and Wold, 1990). Within this
intergenic region, just 3¢ of the Mrf4 gene, an enhancer element
has been identified that directs early expression of Myf5 in the
epaxial dermomyotome (Summerbell et al., 2000; Teboul et al.,
2002). Gustafsson et al. have reported that this element
responds to sonic hedgehog signalling, which is required for
the expression of Myf5 specifically in this epaxial domain
(Borycki et al., 1999; Gustafsson et al., 2002). Also in the
intergenic region between Mrf4 and Myf5, further regulatory
regions have been described, including one that directs
expression to the branchial arches (Patapoutian et al., 1993;
Summerbell et al., 2000) and another that leads to expression
in the neural tube (Summerbell et al., 2000). Within the Myf5
gene itself, an enhancer that directs expression to the hypaxial
domain of the somite has been identified (Summerbell et al.,
2000). In the genomic DNA lying upstream of the Mrf4-Myf5
genes, there are a number of regulatory regions, including one
responsible for maintenance of Myf5 expression (–88 kb to –81
kb) in some muscles of the trunk and head and others
responsible for aspects of Myf5 expression in the hypaxial
somite, arches and hypoglossal cord (Carvajal et al., 2001a;
Carvajal et al., 2001b; Hadchouel et al., 2000). In particular, a
sequence lying between –58 kb and –48 kb from the Myf5 gene
(Hadchouel et al., 2000) directs expression of a transgene to
sites of myogenesis in the somites, hypoglossal cord and limb
buds, as suggested by deletions in this region (Carvajal et al.,
2001a; Zweigerdt et al., 1997), and also to the brain. In this
paper, we present the analysis of this region and show that it
is necessary for transcription of Myf5 at these sites in the
embryo. Different sites are targeted by distinct sequences and,
furthermore, within a single site, regulatory subdomains
emerge that are identified by dissection of the region or
revealed after its deletion. Unexpectedly, a distinct sequence
targets transcription of Myf5 to the central nervous system. At
least three sequences are active at different times and to varying
extents in fore- versus hindlimbs. In the somite, Myf5
expression is regulated by a minimum of six different
sequences, with more than one regulatory module required
even within an ostensibly uniform structure such as the
myotome. The fine analysis of the region located between –58
kb and –48 kb from Myf5, and the consequences of its deletion
add a further dimension to our appreciation of the complexity
of the information that has to be integrated to ensure the
spatiotemporal regulation of this myogenic determination
gene. Furthermore, this analysis reveals subpopulations of cells
that contribute to myogenesis as the embryo develops.
MATERIALS AND METHODS
Plasmid transgene constructions
All plasmid constructs used in this study, except p-58/-48tk-nlacZ and
p8.8 (Summerbell et al., 2000), are derived from pbaMyf5-nlacZ,
(Hadchouel et al., 2000), containing the nlacZ reporter gene with 2.6
kb of Myf5 5¢ flanking sequence that includes the Myf5 branchial arch
element located between –1.7 kb (NheI site) and –561 bp (BsaBI site),
the neural tube element located between –561 bp and –141 bp (XbaI
site) (Summerbell et al., 2000), and the Myf5 minimal promoter (–141
bp from the Cap site). We refer to this construct as pMyf5-nlacZ. p-58/-
48Myf5-nlacZ (Hadchouel et al., 2000) was totally digested by XhoI
then partially digested by SauIIIA and religated to itself to create a
random 5¢ deletion series of the –58/–48 fragment. Among the
resulting constructs, p-56.4/-48Myf5-nlacZ and p-53.3/-48Myf5-nlacZ
were selected for micro-injection. p-58/-48Myf5-nlacZ was digested by
NcoI and HindIII, and religated on itself to obtain p-58/-54Myf5-nlacZ.
A 1.4 kb AvaI or a 2.9 kb AvaI-AccI fragment was subcloned in pMyf5-
nlacZ to create p-58/-56.6Myf5-nlacZ or p-56.6/-53.7Myf5-nlacZ,
respectively. A 5 kb ClaI-XhoI fragment located between –63 and –58
was subcloned in p-58/-54Myf5-nlacZ to obtain p-63/-54Myf5-nlacZ.
The fragments –58/–57, –57.5/–56.6 and –57.5/–57 were synthesized
by PCR using the Advantage 2 Taq polymerase (Clontech), with XhoI
and HindIII sites added to 5¢ and 3¢ primers, respectively. The forward
and reverse primers used to generate the –58/–57, –57.5/–56.6 and
–57.5/–57 fragments were, respectively: fwd (5¢ -GGG CTC GAG
CAA TAT AAT GTC-3¢ ), rev (5¢ -AAA AAG CTT TTT CTC TTA
AGA GAG AGC TTG GGC ACC-3¢ ); fwd (5¢ -AAA CTC GAG GTA
TGT TTG TTG GAA AGG CC-3¢ ), rev (5¢ -AAA AAG CTT GGG
ATT TGT ACC TCC ATC AGA TGG G-3¢ ); and fwd (5¢ -AAA CTC
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GAG GTA TGT TTG TTG GAA AGG CC-3¢ ), rev (5¢ -AAA AAG
CTT TTT CTC TTA AGA GAG AGC TTG GGC ACC-3¢ ). The PCR
products were checked by sequencing (Genome Express) and cloned
into pMyf5-nlacZ, in front of the transgene.
p-58/-48tk-nlacZ was created by subcloning the 10 kb XhoI-HindIII
fragment located between –58 and –48 kb into ptk-nlacZ, which
contains the nlacZ reporter gene under the control of the thymidine
kinase (tk) promoter isolated from pBLCAT2 (Luckow and Schütz,
1987).
BAC transgene constructions
All BAC deletion constructs are based on BAC195APZ (Carvajal et
al., 2001a). For BAC195∆54-49, homology arms were synthesized by
PCR amplification of BAC195APZ with the following primer pairs:
5¢ homology arm (1220 bp), ∆54-49.5F (5 ¢ -TTA GAT CTA TTG TCA
GAA GAA TAG AGA AAA GGA-3 ¢ ) and ∆54-49.5R (5¢ -AAG GAT
CCG ATC TTG AAG AAA TTT TGG TAA TTC C-3¢ ); 3¢ homology
arm (1209 bp), ∆54-49.3F (5 ¢ -GTT TTG ATA GAG GAT GAA TAC
TCA A-3¢ ) and ∆54-49.3R (5¢ -TCA TTT GAA TAG AGA CCT AAA
GAT C-3¢ ). The 5¢ homology arm fragment was cloned into pCRII
(Invitrogen) to generate p∆54-49.5. The 3¢ homology arm fragment
was digested with XhoII and cloned into a BamHI-digested p∆54-49.5
to give pCas∆54-49.
For BAC195∆59-54, homology arms were synthesized by PCR
amplification of BAC195APZ with the following primer pairs: 5 ¢
homology arm (140 bp), ∆59-54.5F (5 ¢ -CTG ATG CAT GCT TGT
CAT GGT-3¢ ) and ∆59-54.5R (5¢ -TGG ATC CTG AAA ACG TGA
GGC ACC GGA GG-3 ¢ ); 3¢ homology arm (140 bp), ∆59-54.3F (5 ¢ -
CCA TAG GAA TTA CCA AAA TTT CTT C-3 ¢ ) and ∆59-54.3R (5¢ -
CGT AAA CCA TTA AGA TGG TGG-3 ¢ ). To generate the deletion
cassette, 5¢ and 3¢ homology arms were digested with BamHI and
XhoII, respectively, ligated and re-amplified using ∆59-54.5F and
∆59-54.3R. 
For BAC195∆63-48, homology arms were synthesized by PCR
amplification of BAC195APZ with the following primer pairs: 5 ¢
homology arm (145 bp), ∆63-48.5F (5 ¢ -AAA TGT GCT AAT GTG
GAG AGG-3¢ ) and ∆63-48.5R (5¢ -CAC ATA CAC AAC TTC ACA
AAA GCT ATG CCA GGT TGC TAT CCC TCC-3 ¢ , including a
24mer tail homologous to the 5 ¢ -end of the 3 ¢ homology arm); 3 ¢
homology arm (144 bp), ∆63-48.3F (5 ¢ -AGC TTT TGT GAA GTT
GTG TAT GTG-3¢ ) and ∆63-48.3R (5¢ -GTC TGC ATG GAA CTA
GTG TAA-3¢ ). To generate the deletion cassette, 5¢ and 3¢ homology
arm fragments were gel purified, mixed in a 1:1 ratio, denatured for
5 minutes at 95°C and left to re-anneal at 37°C for 30 minutes.
Standard PCR-mix, not including primers, was added and the reaction
incubated at 72°C for 30 minutes. The extended products were then
re-amplified by PCR using ∆63-48.5F and ∆63-48.3R. 
For BAC195∆54-49, pCas∆54-49 was digested with NotI to excise
the deletion cassette. Fragments were isolated by gel electrophoresis
and subcloned into a pSV-RecA vector (Yang et al., 1997), which had
been modified by introducing a single NotI site replacing the SalI
cloning site (D.C., J.J.C. and P.W.J.R., unpublished). Generation of
the deleted BAC with this plasmid construct was carried out as
previously described (Cox et al., 2002). For the generation of other
BAC deletion constructs, we used our own modification of the linear
recombination method (Lee et al., 2001; Swaminathan et al., 2001).
BAC195∆59-54 was generated by introducing the 5 kb deletion in
BAC195APZ, while BAC195∆63-48 was generated by deleting the
entire region from BAC195∆59-54.
For BAC195∆59-54 and BAC∆63-48, 25 ng of DNA from each
BAC was used to transform electrocompetent E. coli DY380 cells.
Single colonies growing under chloramphenicol (CAM) selection
were analysed to check that BACs transferred to the new host were
not rearranged. Single colonies were isolated and grown on LB-CAM
media overnight at 32°C with constant agitation. This culture (220 m l)
was used to seed 11 ml of LB-CAM. Cells were incubated at 32°C
with shaking (>250 rpm) until the OD600 was between 0.5 and 0.7.
Cultures were then incubated at 42°C for 15 minutes, transferred to
wet ice and left to cool down for at least 20 minutes. Cells were
washed three times in ice-cold H2O and electroporated immediately
after the last wash. Deletion cassettes were denatured by 10 minutes
incubation in 300 mM NaOH, ethanol precipitated, resuspended in 20
m l of cold H2O and mixed with the electrocompetent DY380 cells
carrying the BAC of interest. Electroporation conditions were as
follows: 1.75 kV, 200 Ohms, 25 m F. After electroporation, cells were
diluted and plated into a single 96-well plate at a density of 10-30
cells/well. After overnight growth at 32°C, colony pools were
screened by PCR using primers outside the deletion cassette. Positive
pools were diluted and plated on LB-agar CAM to obtain ~250
colonies/plate and incubated overnight at 32°C. Single colonies were
picked onto 96 well plates, grown overnight at 32°C with constant
agitation and PCR-screened with the same primer pair to identify
positive clones. All clones were sequenced to confirm the deletion,
and the integrity of the sequences corresponding to the homology
arms. Furthermore, positive clones were digested with a panel of
restriction enzymes to ensure no additional deletions, insertions or
rearrangements had occurred. 
Generation of transgenic mice
BAC DNA purification was carried out as described previously
(Carvajal et al., 2001a) and plasmid fragments as described elsewhere
(Kelly et al., 1995). Transgenic mice were generated by
microinjection of purified BAC or plasmid DNA into fertilized
(C57BL/6J · SJL) or (CBA· C57BL/6J) F2 eggs at a concentration of
Table 1. Transient transgenic embryos
Transgene E9.5/E9.75 E10.5/E.11 E11.5/E12 E12.5 E13.5/E14.5
–58/–48 tk-nlacZ 8 (8)
–56.4/–48 Myf5-nlacZ 8 (12)
–53.3/–48 Myf5-nlacZ 2 (4) 7 (10) 3 (4)
–56.6/–53.7 Myf5-nlacZ 4 (6) 4 (6)
–58/–54 Myf5-nlacZ 8 (8) 2 (2) 6 (8)
–58/–56.6 Myf5-nlacZ 8 (9) 3 (3)
–58/–57 Myf5-nlacZ 6 (6)
–57.5/–56.6 Myf5-nlacZ 6 (8)
–57.5/–57 Myf5-nlacZ 4 (9) 3 (3) 3 (4)
–63/–54 Myf5-nlacZ 8 (13) 3 (3) 5 (6)
BAC 195APZ 3 (3)
BAC 195APZD 63-48 3 (3)
BAC 195APZD 59-54 8 (8) 1 (2) 4 (4) 3 (3)
BAC 195APZD 54-49 6 (6)
Numbers are given at each stage for embryos that showed Myf5-specific X-gal staining. The numbers in brackets indicate the total number of transgenic
embryos examined.
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~1-2 ng/m l using standard techniques (Hogan et al., 1994). Injected
eggs were reimplanted the same day or the day after the injection into
pseudopregnant (C57BL/6J · CBA) F1 foster mothers.
Identification of transgenic animals
DNA was prepared from mouse tails or, for transient transgenics, a
region of the embryo, and analysed by PCR, using standard
techniques.
Analysis of transgene expression
Heterozygous transgenic males were crossed with non-transgenic
females ([C57BL/6J· SJL or C57BL/6J · CBA] F1). Embryos were
dated, taking E0.5 as the day of the appearance of the vaginal plug.
Transient transgenic embryos were dated taking the day of
reimplantation into the pseudo-pregnant foster mothers as E0.5.
Numbers of positive transient transgenics analysed at each time point
are indicated in Table 1. The following transgenic lines, with numbers
given in brackets, were also analysed: –58/–48Myf5-nlacZ (2),
BAC195Z (6), BAC195APZ (5), BAC195 D 63-48 (3), BAC195 D 59-54
(3) and BAC195 D 54-49 (4).
X-gal staining: embryos were dissected in PBS, fixed in 4%
paraformaldehyde for 5 to 60 minutes depending on the age of the
embryo, or in Mirsky’s Fixative (National Diagnostics) for 1 hour to
overnight, rinsed twice in PBS and stained in X-gal solution
(Summerbell et al., 2000; Tajbakhsh et al., 1996a) at 37°C from 2
hours to overnight. Transgenic embryos were examined by whole-
mount microscopy or cryostat sectioning, as described previously
(Kelly et al., 1995).
Immunofluorescence: cryostat sectioning and immunofluorescence
experiments were performed as described elsewhere (Teboul et al.,
2002), with use of a monoclonal anti-myosin heavy chain antibody
(MF20, dilution 1:50) from the Developmental Studies Hybridoma
Bank.
RESULTS
In order to investigate the spatiotemporal regulation of Myf5
expression by the sequence that we had identified between –58
kb and –48 kb (Hadchouel et al., 2000), we constructed
transgenes containing fragments of this region as indicated in
Fig. 1A. They were placed in front of a proximal Myf5 sequence
(2.6 kb), which includes the promoter, and ventral neural tube
and branchial arch elements (Summerbell et al., 2000), which
serve as positive controls for expression of the nlacZ transgene.
In Fig. 1B, we show the nlacZ expression at embryonic day
(E)11.5 of a transgene where the reporter is regulated by the
–58/–48 sequence with a heterologous thymidine kinase
promoter. The expression pattern at this stage was similar to that
previously described with the Myf5 promoter (Hadchouel et al.,
2000). The fact that the sequence acts with a heterologous
promoter, independently of position relative to the promoter
suggests that it has the properties of an enhancer. 
The –53.3/–48 region directs expression mainly to
the most anterior somites and to the hindlimb
The region between –53.3 kb and –48 kb placed in front of the
proximal Myf5 sequence directed reporter gene expression to
musculature in the cervical region and in the limb buds at E12
as shown in Fig. 2A. There was also labelling at this stage of
some facial muscles derived from the branchial arches because
of the branchial arch element. Hindlimb muscle masses were
more strongly labelled than those in the forelimb, despite the
anteroposterior developmental gradient (see Fig. 1B). With a
–56.4/–48 Myf5-nlacZ transgene, the hindlimb bud was also
more strongly labelled than the forelimb (Fig. 2B) at E11. b -
galactosidase-positive cells were present in anterior somites,
and the section shown in Fig. 2C,D indicates that these
represent a subpopulation of differentiated muscle cells in the
myotome, which is marked by myosin heavy chain expression.
The myotomal expression is also seen with the –53.3/–48
Myf5-nlacZ transgene (results not shown). In some embryos
where transgene expression was particularly strong, labelled
cells were also detected in more posterior myotomes. At E10.5,
when Myf5 is normally expressed in the forelimb, no b -
galactosidase positive cells were detectable with these
transgenes in the limb buds. At this earlier stage, occasional
embryos showed weak myotomal labelling, varying in its
extent on the anteroposterior axis. At later stages (e.g. E13.5)
shoulder and limb muscles continued to be positively labelled
with this transgene (results not shown).
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Fig. 1. The regulatory region at –58/–48 kb upstream of Myf5. (A) Schematic representation of the different fragments of the –58/–48 kb region
and its upstream extension to –63 kb, which are subcloned in front of the Myf5-nlacZ cassette (2.6 kb, including a branchial arch element,
neural tube element and the Myf5 promoter) (Hadchouel et al., 2000; Summerbell et al., 2000). For each construct, the cloned region is
indicated by a black line. Distances in kb are from the Myf5 Cap site. (B) The nlacZ expression pattern, revealed by X-gal staining, is shown for
an embryo at E11.5 (40-45 somites) with a –58/–48 tk-nlacZ transgene, where the region between –58 kb and –48 kb has been placed in front
of a heterologous thymidine kinase promoter. 
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The –56.6/–53.7 region directs expression in the
central nervous system
In Fig. 2B, expression in the brain and ventral neural tube (Fig.
2C) was detected, suggesting that an element responsible for
the transcription of Myf5 in the central nervous system
(Tajbakhsh and Buckingham, 1995) is located between –56.4
kb and –53.3 kb (compare Fig. 2A with 2B). Fig. 3A shows that
this is indeed the case. With a –56.6/–53.7 Myf5-nlacZ
transgene, prosomeres p1 and p4 were labelled. A section
through prosomere p1 (Fig. 3C) shows b -galactosidase-positive
cells in this region of the diencephalon, where the endogenous
gene is expressed, extending from the mantle layer into the
subventricular zone where neuronal precursors are present. In
contrast, the labelled cells in prosomere p4 in a section through
the mesencephalon (Fig. 3D) were confined to the outer layer
of the neuroepithelium where differentiated neurones are
present, as seen with the endogenous gene (Daubas et al., 2000;
Tajbakhsh and Buckingham, 1995). Expression of the transgene
was also seen in cells in the ventral neural tube (Fig. 3B). As
in the case of prosomere p1, expression was in the same region,
but not identical to that seen with the endogenous gene, possibly
because further regulatory elements which refine and restrict
transcription are absent from the 2.9 kb fragment of the
enhancer present in this transgene. As the 2.6 kb proximal
region of Myf5, which is present in this and other transgenes,
contains a neural tube element (Summerbell et al., 2000) and
the complete –58/–48 region, when placed in front of a minimal
tk promoter (Fig. 1B), also directs expression to the ventral
neural tube, we conclude that two distinct elements are
responsible for this site of expression, and probably cooperate
to target the subset of neurones marked by transcription of the
endogenous gene (Tajbakhsh et al., 1994).
The –58/–56.6 region contains elements which target
limb buds, hypoglossal cord, and distinct regions of
the somite
A transgene with the region between –58 and –54 kb directed
Myf5-nlacZ expression in the central nervous system, as
expected, and at additional sites in the embryo (Fig. 4). At E9.75
(Fig. 4A), there was no labelling in the most caudal immature
somites, where myogenesis is initiated by the early epaxial
enhancer that activates Myf5 transcription in the dermomyotome
(Teboul et al., 2002). In more mature somites, b -galactosidase
positive cells were present in the myotome, underlying the
epithelial dermomyotome in a central position (Fig. 4B) where
muscle differentiation first takes place (Spörle, 2001). This
corresponds to the region of the myotome that is revealed when
the earlier epaxial enhancer is deleted (Teboul et al., 2002). At
E10.5 (Fig. 4C), labelled cells continued to be located in the
central part of the myotome. By E11.5 the expression pattern in
the somite has changed (Fig. 4D). Cells in the epaxial myotome
were still b -galactosidase-positive in a region that is intercalated
between epaxial most and hypaxial domains of the myotome
(Fig. 4E). Labelling was now also detectable in more mature
anterior somites in the epaxial lip of the dermomyotome and, in
the interlimb region, the hypaxial somitic bud also contained b -
galactosidase-positive cells (Fig. 4E). At this stage, the epithelial
structure of the dermomyotome is no longer present except at
the extremities of the somite. Some labelled cells could also be
seen in the hypaxial myotome. In previous studies, the –58 kb
end point was chosen arbitrarily. Given that sequences up to this
point conferred muscle expression, we tested more upstream
sequences for activity in transgenic assays. In Fig. 4F, an E11.5
Fig. 2. The –53.3/–48 region drives Myf5-nlacZ expression mainly in
cervical somites and the hindlimb bud. X-gal staining at E12, with a
–53.3/–48 Myf5-nlacZ transgene (A), and at E11.0, with a –56.4/–48
Myf5-nlacZ transgene (B). Black arrows indicate X-gal staining in
fore- and hind-limbs. b -galactosidase-positive cells are detected in
the brain in prosomeres p1 and p4 (white arrowheads). The embryo
shown in B was sectioned at the level of the cervical somites (white
line) and the corresponding transverse cryostat section is shown
under phase contrast (C) or fluorescence (D), after immunoreaction
with an antibody against muscle myosin heavy chain (red labelling)
to show differentiated muscle cells in the myotome, the extent of
which is indicated by white arrows. Black arrowhead in C indicates
b -galactosidase-positive neurones within the ventral neural tube
(NT). DRG, dorsal root ganglia.
Fig. 3. The –56.6/–53.7 region drives Myf5-nlacZ expression only in
the central nervous system. (A) X-gal staining at E11.5 of an
embryo, with a –56.6/–53.7 Myf5-nlacZ transgene, showing nlacZ
expression in the embryonic brain (prosomeres p1 and p4) and in the
neural tube. The embryo in A was sectioned at levels indicated by the
white lines, and sections at these levels are shown in B-D. b -
galactosidase-positive cells are detected in the ventral neural tube (B)
and in the neuroepithelium at the levels of prosomeres p1 (C) and p4
(D). In these brain sections, telencephalic vesicles are on the right.
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embryo with a –63/–54 Myf5-nlacZ transgene is shown. The X-
gal labelling is essentially similar to that with the –58/–54
sequence. This additional 5 kb of 5¢ sequence therefore did not
extend the expression pattern.
Fig. 5A shows that a –58/–56.6 Myf5-nlacZ transgene,
which no longer contains the distal central nervous system
element, directed expression at E11.5 to the sites of
myogenesis shown in Fig. 4D. The –58/–57 part of this
fragment (Fig. 5B) continued to direct expression in the
hypoglossal cord and limb buds, whereas labelling in the
somite was confined to the epaxial and hypaxial extremities
(Fig. 5C), where b -galactosidase-positive cells were clearly
seen in the epithelial structures of the epaxial lip (Fig. 5D) and
hypaxial somitic bud (Fig. 5E). In contrast, a –57.5/–56.6
fragment directed expression to the intercalated domain of the
epaxial myotome (Fig. 5F,G), showing that this site of Myf5
transcription in the somite is under distinct regulation. This
transgene showed variable expression in the epaxial lip and
somitic bud. Both the –58/–57 and –57.5/–56.6 fragments
directed expression in the limb buds and hypoglossal cord (Fig.
5B,F). Consistent with this, the overlapping 500 bp fragment
(–57.5/–57) also directed expression to these sites (Fig. 5H).
This fragment also showed strong expression in the hypaxial
somitic bud and in the epaxial lip of the dermomyotome.
Deletion of the –58/–48 region reveals its essential
role in directing Myf5 expression in the embryo
The preceding observations demonstrate that the –58/–48 region
directs transcription of Myf5 to the brain, limbs, hypoglossal
cord and to specific domains of myogenesis in the somite. In
order to establish whether this region is necessary for Myf5
expression at these sites in the context of the locus, it was deleted
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Fig. 4. The –58/–54 region drives Myf5-nlacZ expression to several
sites of myogenesis in the somites, limb buds and hypoglossal cord.
(A,C,D) X-gal staining of an embryo with a –58/–54 Myf5-nlacZ
transgene at E9.75 (A, 26 somites), E10.5 (C, 30 somites) and E11.5
(D, 36 somites). At E9.75, b -galactosidase-positive cells are detected
in the developing myotome in the central epaxial region, as shown in
a transverse cryostat section (stained with Eosin) (B) of the same
embryo shown in A (white line indicates level of sectioning). At
E10.5 (C), Myf5-nlacZ expression is still restricted to the same area of
the myotome. It is detected in the extremities of the more mature
somites at E11.5 (D). (E) Phase contrast microscope view of a section
in the interlimb region of the embryo shown in D (white line indicates
level of sectioning) where both the epaxial lip of the epithelial
dermomyotome and the hypaxial somitic bud contain cells with blue
nuclei (black arrowheads). At this stage, there is strong X-gal staining
in the forelimb buds and labelling is also detectable in the less mature
hindlimb buds. Cells in the hypoglossal cord are also positive for b -
galactosidase. (F) X-gal staining of an embryo at E11.5 (40 somites),
with a –63/–54 Myf5-nlacZ transgene showing a pattern which is
essentially similar to that shown in D. With these two constructs,
Myf5-nlacZ activity is also detected in the brain and neural tube,
owing to the central nervous system element (–56.6/–53.7), and in the
branchial arches, owing to the control branchial arch sequence. There
is also ectopic labelling of head mesenchyme, which is particularly
notable in C. NT, neural tube; HC, hypoglossal cord.
Fig. 5. The –58/–56.6 region contains elements that direct transgene
expression to distinct regions of the somite, as well as to the limb
buds and hypoglossal cord. X-gal staining of embryos at E11.5 (38-
40 somites) in which the Myf5-nlacZ transgene contains a –58/–56.6
kb fragment (A) or subfragments of it: –58/–57 (B), –57.5/–56.6 (F)
or –57.5/–57 (H). In A, expression is no longer seen in the brain
(compare with Fig. 4D), but in somites, limb buds and hypoglossal
cord. In B, the –58/–57 subfragment directs expression to the limb
buds and hypoglossal cord (black arrow) and to the epaxial and
hypaxial extremities of the somite. The cryostat section in C (stained
with Eosin), corresponds to a transverse section (white line in B) at
the thoracic level of embryo (B). Higher magnifications (D,E) show
b -galactosidase-positive cells in the epithelial structures of the
epaxial lip (D) and hypaxial somitic bud (E). In F, somitic expression
is mainly seen in the epaxial intercalated region of the myotome,
shown on a transverse cryostat section at the thoracic level (white
line) in G. The outline of the myotome, which is marked by immune
staining with a myosin heavy chain antibody (not shown) is
presented as a broken line. In H, the 500 bp (–57.5/–57) fragment
directs expression to the limb buds, hypoglossal cord, and epaxial
and hypaxial extremities of the somite.
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from BAC195APZ, which contains 195 kb of genomic DNA 5¢
to the Myf5 gene and 39.6 kb 3¢ to it. This BAC recapitulates the
complete pattern of Myf5 expression, as monitored with an nlacZ
reporter sequence, introduced at the ATG of the gene (Carvajal
et al., 2001a). The deletion extends from –63 kb to –48 kb, in
order to include any potential sequences that reinforce activity
at the 5¢ end. As expected, comparison of the nlacZ expression
profile in the deleted BAC195APZD 63-48 and wild-type
BAC195APZ constructs at different developmental stages
showed no difference at E8.5 when b -galactosidase-positive
cells, which are located in the epaxial dermomyotome, were
present in both cases (results not shown). At this stage, Myf5
expression is directed by the early epaxial enhancer situated at
–6.5 kb from the Myf5 gene (Teboul et al., 2002). At E9.0 (Fig.
6A,B), Myf5 expression in immature caudal somites was
unaffected by the deletion. In more mature somites, the pattern
of dermomyotomal expression was skewed towards the caudal
edge of the somite (Fig. 6B), compared with that seen in the
undeleted BAC (Fig. 6A). At E11.5, myotomal expression was
perturbed in BAC195APZD 63-48 with foreshortening of the
epaxial and hypaxial extent (Fig. 6C-F), as shown on interlimb
level sections (Fig. 6G,H), which also suggest loss of b -
galactosidase-positive cells in the central epaxial domain. At this
stage, it was clear that all brain and limb expression of Myf5 was
abolished by the deletion (Fig. 6D). At E10.5, when expression
of the transgene begins to be detectable in the forelimb bud, this
is not seen with the deleted BAC (results not shown). Expression
in the hypoglossal cord is also affected at this stage. These results
demonstrate that the region deleted in the BAC is essential for
Myf5 expression in the limb buds, in the hypoglossal cord and
in the brain, and for aspects of (dermo)myotomal expression,
notably those in the epaxial and hypaxial extremities of more
mature somites. The epaxial intercalated expression in the
myotome is more difficult to follow in the deleted BAC,
probably because it tends to be obscured by more proximal
elements that also target b -galactosidase in the myotome, and in
particular by the perdurance of b -galactosidase as a result of the
activity of the early epaxial enhancer (Teboul et al., 2002). This
is certainly also the case for the element at –53.3/–48 that targets
anterior somites. 
Further deletions of the 5¢ (BAC195APZD 59-54) and 3¢
(BAC195APZD 54-49) parts of the region are shown in Fig. 7
and compared with p8.8, a plasmid that contains the intragenic
hypaxial element (Summerbell et al., 2000) and the Mrf4/Myf5
intergenic region, which includes the early epaxial enhancer
(Summerbell et al., 2000; Teboul et al., 2002). At E9.5,
BAC195APZD 63-48 (Fig. 7A) and BAC195APZD 59-54 (Fig.
7B) showed the skewed dermomyotomal expression with a
pronounced caudal somitic expression already noted in Fig. 6,
which is due to this intragenic element (Fig. 7D). By contrast,
epaxial dermomyotome expression in newly formed somites,
directed by the early epaxial enhancer (Teboul et al., 2002), is
maintained (Fig. 7A-C). Deletion of only the 3¢ half of the
region in BAC195APZD 54-49 (Fig. 7C) corrects this pattern,
probably owing to the dermomyotomal suppressor element
Fig. 6. The –63kb to –48kb region is necessary for Myf5 expression
in limb buds, central nervous system and domains of the somite.
Comparison of X-gal staining profiles between embryos of
BAC195APZ (A,C,E) and BAC195 A PZD 63-48 (B,D,F) transgenic
lines at different stages of embryonic development. (A,B) At E9.0,
the transgene is activated in the epaxial somitic lip as directed by the
early epaxial enhancer (Teboul et al., 2002). (C,D) At E11.5, limb
and brain expression are missing from the deleted BAC line.
Expression in the thoracic somites at this stage does not comprise the
full epaxial-hypaxial myotome extension, whereas staining shows a
clear caudal bias as shown on higher magnification of these regions
of E11.5 embryos (E,F). Expression in the thoracic somites at this
stage does not comprise the full epaxial-hypaxial extent of the
myotome (indicated by the red lines in E,F). (G,H) Transverse
cryostat sections, stained with Eosin and X-gal from the thoracic
level (white lines in C,D) of the embryos shown in C,D. Arrows in H
indicate the full extent of the myotome (see G).
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previously mapped between –59 kb and –8.8 kb (Carvajal et al.,
2001a), and maintains the epaxial myotome expression directed
by the –58/–54 region (Fig. 4A,B). At E11.5, BAC195APZD 54-
49 (Fig. 7G) showed the full epaxial/hypaxial extent of Myf5
expression with labelling of the epaxial lip and notably the
hypaxial somitic bud, which is missing in BAC195APZD 63-48
and BAC195APZD 59-54 (Fig. 7E,F). Notably in these BACs,
expression in prosomeres p1 and p4 was missing (Fig. 7E,F,
compare with 7G). At this stage the intragenic region in p8.8
still directed caudal somitic expression and a pronounced band
of labelling in the myotome (Fig. 7H). At E11.5, the BAC
deletions clearly confirmed observations on limb bud
expression. In the absence of the 5¢ half of the region, with
BAC195APZD 59-54, this was weak, but more pronounced in
the hindlimb, in keeping with our observations on the –53.3/–48
sequence (Fig. 2A), while the presence of the 5¢ sequence in
BAC195APZD 54-49 directed strong forelimb and weaker
hindlimb expression, following the normal developmental
gradient. 
At E13.5, some trunk and limb musculature continued to be
compromised with BAC195APZD 63-48; however, labelling of
limb muscle masses, particularly in the forelimb was now
detectable (Fig. 8B). Observations on fore- and hindlimbs from
E12.5 to E14.5 are shown in Fig. 8, for deleted and wild-type
BACs. In the forelimb at E12.5 (Fig. 8D,E), more proximal
muscles were mainly labelled in the deleted BAC, but by E13.5
(Fig. 8F,G) most muscle masses appeared to be labelled. This
was also true for the hindlimb (Fig. 8H-K) with a delay of 1
day. We therefore conclude that the –58/–48 region is essential
for early expression of Myf5 in the limb buds, but that other
elements located elsewhere in the locus direct later expression
of the gene in the limbs. This expression initially overlaps with
that directed by the –58/–48 region, which is still active in the
limbs at E13.5 (Fig. 8C).
DISCUSSION
The dissection of the region situated between –58 kb and –48
kb upstream of Myf5 demonstrates that distinct regulatory
elements direct transcription of this myogenic determination
gene to the limb buds and hypoglossal cord, to sites of
myogenesis in the somite and to specific regions of the central
nervous system, where the endogenous gene is transcribed, in
the mouse embryo (Table 2). The complete region would
appear to be a composite of elements which function out of the
normal context and with a heterologous tk promoter (Fig. 1B
and results not shown). Deletions of this region, in the context
of a large BAC, which recapitulates the endogenous expression
of Myf5, show that the regulatory elements are necessary for
these important aspects of the spatiotemporal regulation of
Myf5 transcription. Furthermore, this analysis shows that more
than one element targets the same site, revealing multiple
phases of myogenesis in the different domains where Myf5
regulatory elements orchestrate the initiation of skeletal muscle
formation.
Myf5 transcription in the central nervous system
The region between –56.6 kb and –53.7 kb specifically targets
prosomeres p1 and p4 in the brain where endogenous Myf5
transcripts are detected and deletion of this region shows that
it is required for transcription of the gene at these sites. It also
directs expression to the ventral neural tube. The fact that this
site of transcription is not entirely coincident with that of the
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Fig. 7. Multiple deletions within





BAC195APZ∆63–48 (A,E), D 59-
54 (B,F), D 54-49 (C,G) and p8.8
(D,H) constructs. At E9.5 (A-D),
deletion of the entire –63 kb to
–48 kb region (A) or the –59 kb




the expression pattern obtained
with plasmid p8.8 (D), and
driven by the intragenic enhancer
element (Summerbell et al.,
2000). Deletion of the –54 kb to
–49 kb region does not seem to
affect the expression pattern at
this stage, as it results in a
similar pattern to the wild type.
This suggests that the –59 kb to
–54 kb interval contains the predicted suppressor of the dermomyotome element. At E11.5 (E-H), limb expression is missing in the –63 kb to –48
kb deletion (E), whereas expression in both limbs is seen with both the half-deletion constructs (F,G). In the –59 kb to –54 kb deletion (F),
expression in the hindlimb is stronger, whereas in the –54 kb to –48 kb deletion, the relative intensity of expression between fore- and hindlimbs is
reversed. This suggests that both regions are required for the full recapitulation of limb expression at this stage. (H) The intragenic region in p8.8
directs a pronounced band of labeling in the myotome of more mature somites.
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endogenous gene (Tajbakhsh and Buckingham, 1995;
Tajbakhsh et al., 1994) probably reflects the action of other
sequences in the locus in restricting and refining the expression
pattern. Indeed, the isolated fragment also tends to be
transcribed more widely in prosomere p1. This effect is clearly
distinguishable from ectopic expression in head mesenchyme,
which is seen sporadically with many Myf5 transgenes. In the
case of the neural tube, another element located within the
Myf5 proximal region (Summerbell et al., 2000) also directs
expression to this site. The upstream sequence, like this
proximal sequence, can act independently, as seen in –58/–48
tk-nlacZ transgenic embryos. There is no apparent function
associated with the activation of Myf5 in specific neurones of
the central nervous system, and based on observations that
canonical Wnt signalling is implicated in Myf5 transcription in
both somites (Tajbakhsh et al., 1998) and the central nervous
system (Daubas et al., 2000), we had speculated that the latter
is caused by inappropriate triggering of a somite regulatory
element. This is clearly not the case because the –56.6/–53.7
sequence only directs Myf5 transcription to the specific sites in
the central nervous system. It is probable that the region
between –58 kb and –48 kb was put together by evolutionary
tinkering (‘bricolage moléculaire’) (Jacob, 1977), which may
have led to the inclusion of an unwanted regulatory element.
However, it is surprising that it should have conserved its
function in the absence of apparent selective pressure. It is also
surprising that a second neural tube element is present in the
5¢ proximal region of Myf5. Although the Myf5 protein is not
detectable and does not appear to play a role in the embryonic
central nervous system (Daubas et al., 2000), a possible role in
the postnatal neural tube and brain was not examined because
of the lethality of the Myf5 mutation at birth.
Fig. 8. Deletion of the –63 kb to –48 kb region reveals an additional
element(s) directing a second phase of limb expression. Transgenic
embryos at E13.5 where nlacZ expression is directed by
BAC195APZ (A) or by BAC195APZ D 63–48 (B). In C, an embryo
with the –58/–48 Myf5–nlacZ transgene is shown. Comparison of the
expression patterns of the limbs between embryos of BAC195APZ
(D,F,H,J) and BAC195APZ D 63-48 (E,G,I,K) transgenic lines. (E) At
E12.5, all pre-muscle masses show weak X-gal staining, not seen in
the hindlimb at this stage (not shown). (F,G) By E13.5, the forelimb
expression pattern driven by the two constructs is similar. (I) Very
weak expression is detected in hindlimb pre-muscle masses. (J,K) By
E14.5, the hindlimb expression pattern driven by the two BAC
constructs is indistinguishable. 
Table 2. Regulatory elements within the –58/–48 kb region: a summary of transgenic results
Sequence interval (kb)
Sites of expression –58/–54 –58/–57 –57.5/–57 –57.5/–56.6 –56.6/–53.7 –53.3/–48
Somites
Early epaxial and later intercalated epaxial myotome + N.D. – N.D. – N.D.
Intercalated epaxial myotome + – – + – –
Subset of cells in central/hypaxial myotome (mainly anterior somites) – – – – – +
Later hypaxial somitic bud + + + (+) – –
Later epaxial lip + + + (+) – –
Limbs
Forelimb + + + + – (+)
Hindlimb + + + + – +
Hypoglossal cord + + + + – –
Central nervous system
Brain prosomeres p1, p4 + – – – + –
Ventral neural tube + – – – + –
These results lead to the conclusion that, in somites, the –57/–56.6 kb fragment directs expression in the intercalated myotome and suggest that in younger
embryos this element targets the early epaxial myotome. Other regulatory elements that direct expression to somites, notably to the early epaxial dermomyotome
(Teboul et al., 2002) and hypaxial myotome (Summerbell et al., 2000), and to later limb muscles, are revealed by deletion of this region, as discussed in the text.
N.D., not done; (), weak.
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Myf5 expression in the limbs
Sequences within the –58/–48 kb region are essential for early
expression of Myf5 in limb buds. An element located between
–57.5 kb and –57 kb directs robust transcription of the nlacZ
reporter to the fore- and hindlimb buds, following the
anteroposterior developmental gradient, in the same
spatiotemporal pattern as the endogenous gene. This 500 bp
sequence, which is conserved between human and mouse, is
therefore a potential target of signalling pathways/transcription
factors responsible for the activation of this myogenic
determination gene once the muscle progenitor cells have
migrated from the somite to the limb bud. The same sequence
also directs activation of Myf5 transcription in the hypoglossal
cord. This is yet another example of multiple elements
targeting the same site, because another element that also
directs expression to the hypoglossal cord is present in the
region between –81 kb and –63 kb (Carvajal et al., 2001b) and
is necessary in the context of the locus. Cells of the hypoglossal
cord also delaminate from the hypaxial dermomyotome of
occipital somites, but move as a coherent mass (Noden, 1983),
with activation of Myf5 before they attain their final location
around the larynx or in the tongue, where they contribute to
the formation of skeletal muscle (Mackenzie et al., 1998). It is
therefore surprising that this different mode of myogenesis is
activated by the same element, and it remains to be seen if the
same regulation is involved. It is also striking that this element
directs reporter gene expression to the hypaxial somitic bud in
the interlimb region, at a stage when this is a remnant of the
epithelial dermomyotome, which still harbours myogenic
progenitor cells that activate Myf5. This is in contrast to cells
of the hypoglossal cord and limb buds, which express Myf5
only when they have left the somite. 
A second element in the region between –53.3 kb and –48 kb
also contributes to Myf5 expression in the limb buds. This
element is more active in the hindlimb, where reporter gene
expression is clearly observed in the developing muscle masses
at a time when b -galactosidase activity is barely detectable in the
forelimb. Deletion of the region between –59 kb and –54 kb,
where the other limb element is located, confirmed this result.
Forelimb expression appears to be delayed and generally weaker,
but seems to extend to most of the muscle masses. This
distinction between fore- and hindlimbs is particularly interesting
in view of the unexpected results of mutations in the Lbx1 and
Mox2 homeobox genes. Despite the fact that they are present in
myogenic cells in fore- and hindlimbs, the absence of Lbx1
seriously compromises the formation of many forelimb muscles
(Brohmann et al., 2000; Gross et al., 2000; Schafer and Braun,
1999), whereas mutations in Mox2 mutants mainly affect
hindlimb muscles (Mankoo et al., 1999). Recently, it has been
shown that Tbx5 and Tbx4 genes are expressed in fore- and
hindlimbs, respectively (Gibson-Brown et al., 1996) and required
for their development (Rodriguez-Esteban et al., 1999). Pitx1
(Logan and Tabin, 1999) is another example of a gene that plays
a role in hind- but not forelimb development. These mutant
phenotypes point to regulatory differences in the limb
environment that the muscle progenitor cells enter, in addition to
potential intrinsic differences in fore- and hindlimb progenitors
themselves. Further analysis of the Myf5 limb element at
–53.3/–48 will provide more insight into the differences in the
regulatory programme between fore- and hindlimbs.
Deletion of the –58/–48 region, although demonstrating that
it is required for early expression of Myf5 in limb buds, also
shows that by E12.5 other regulatory sequences begin to
participate in Myf5 transcription in the muscle masses of the
limbs. This is an autonomous function and therefore not simple
maintenance, because it is initiated in the absence of the
–63/–48 region. All muscles appear labelled eventually by the
BAC transgene with this deletion, although initially this is
more readily detectable in proximal muscles. It may be
associated with the initiation of secondary myogenesis, which
makes a major contribution to the growth of differentiated limb
muscles from about E14 (Ontell and Kozeka, 1984). 
Myf5 expression in the somite
Several sites of myogenesis in the somite are targeted by the
region between –58 kb and –48 kb that, together with the
previously identified early epaxial enhancer (Teboul et al.,
2002), intragenic hypaxial enhancer (Summerbell et al., 2000),
upstream hypaxial sequence (Carvajal et al., 2001a) and
myotome sequence present in the –23 kb region (Hadchouel et
al., 2000), constitute a set of regulatory modules that orchestrate
Myf5 transcription in the somitic cells that form the myotome.
Initially, the early epaxial enhancer (Teboul et al., 2002) activates
Myf5 transcription in the epaxial dermomyotome, from which
cells delaminate, and then, in the presence of Myf5, become
correctly positioned to form the epaxial myotome (Tajbakhsh et
al., 1996b). A second element contained in the –57.5/–56.6
region of the upstream enhancer then activates Myf5
transcription in the epaxial myotome, which, as the
dermomyotome continues to grow in an epaxial direction
(Denetclaw and Ordahl, 2000; Spörle, 2001) and to produce
myogenic precursors, becomes positioned more centrally,
intercalated between epaxial-most and hypaxial components of
the myotome. It is here that transcripts of Mrf4 and those for
differentiation markers, such as myosins (Lyons et al., 1990;
Spörle, 2001), are first detected. Myf5 is required at this stage
to activate Mrf4/myogenin transcription. The –57.5/–57 kb
fragment does not direct epaxial myotome expression, indicating
that the 400 bp at –57/–56.6 kb contains this transcriptional
module. This region is conserved between human and mouse
genomic DNA, in part because it also contains an exon of the
Ptprq gene (Carvajal et al., 2001a). Another regulatory element
contained within –23 kb of Myf5 also targets a subdomain of the
epaxial myotome (Hadchouel et al., 2000). 
The region between –53.3 kb and –48 kb also displays some
somitic activity in a subset of cells in a more hypaxial part of the
myotome. Labelling is seen at E11.5 in the most anterior somites
and later in some muscles anterior to the forelimb. At earlier
stages of development, somitic labelling is only occasionally
seen. More extensive transgene expression in somites on the
anteroposterior axis is also sometimes seen, indicating that the
–53.3/–48 region can potentially direct such transcription. In the
deleted BACs, it is difficult to distinguish the contribution of this
region from that of the intragenic hypaxial enhancer. The
hypaxial enhancer, located within the Myf5 gene (Summerbell et
al., 2000) directs transcription in the early hypaxial myotome, and
labels the caudal edge of the somite. This labelling, together with
that due to the early epaxial enhancer, is evident when the
–63/–48 region is deleted from BAC195APZ. A further hypaxial
element is present in the 5¢ region upstream of –88 kb (Carvajal
et al., 2001a). As the somite matures, and the dermomyotome
disintegrates, epithelial structures, which probably continue to be
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sources of myogenic progenitor cells, are retained at the epaxial
and hypaxial extremities of the somite. The 500 bp fragment at
–57.5/–57 kb, which also directs Myf5 transcription in the limb
buds, targets these sites. The fact that epaxial and hypaxial
extremities of the dermomyotome are targeted earlier by other
regulatory sequences, illustrates the combinatorial action of
elements directing the complete spatiotemporal expression of
Myf5 in the somite. At earlier stages of myogenesis, the somitic
bud contributes to the hypaxial myotome and then to the
formation of body wall and intercostal muscles. The behaviour
and fate of cells in the later somitic bud can now be examined by
means of these regulatory elements. The same is true for the later
epaxial bud in relation to the contribution of the earlier epaxial
dermomyotome, targeted by the early epaxial enhancer (Teboul
et al., 2002).
Analysis of transgenes which direct Myf5 transcription in the
somite would suggest that at least six and possibly eight
different regulatory modules are responsible for spatiotemporal
aspects of this expression. Presumably, this reflects the
complexity of the signals that modulate the construction of the
myotome, from which all the different muscles of the trunk
originate. It probably also reflects the way in which the
mammalian myotome has evolved from the myotome of
more primitive vertebrates, which prefigures simpler
epaxial/hypaxial muscle derivatives, as in the body of fish for
example. The analysis of Myf5 regulation in the zebrafish
embryo suggests that the proximal promoter region can direct
somite expression (Chen et al., 2001). The –58/–48 enhancer
region, together with the early epaxial and hypaxial enhancers
play a major role in the expression of Myf5 in the mouse
somite, whereas the proximal promoter itself appears to have
little or no regulatory capacity (Summerbell et al., 2000).
The way in which Myf5 regulation may have evolved is
intimately related to that of the Mrf4 gene, which is linked to it
in the same locus in all vertebrates examined (Braun et al., 1990;
Miner and Wold, 1990). The expression profiles of these two
myogenic factor genes are distinct. Although Mrf4 appears to be
regulated, in part, by sequences immediately 5¢ to it (Patapoutian
et al., 1993; Pin et al., 1997), it is also dependent on sequences
further upstream (Carvajal et al., 2001a); it will be interesting to
establish to what extent the –58/–48 kb enhancer region interacts
with the Mrf4 promoter, which lies 5¢ to that of Myf5. Another
myogenic factor gene, MyoD, which, like Myf5, plays a role in
skeletal muscle determination (Rudnicki et al., 1993), has a
distal enhancer that is located at –22 kb from the gene
(Goldhamer et al., 1995). This directs early expression at sites
of muscle formation in the embryo, whereas more proximal 5¢
elements are necessary for transcription at later stages of skeletal
muscle development. However, the MyoD enhancer, which is
also active in limb buds, hypoglossal cord and myotome, can be
reduced to a single 258 bp core element (Goldhamer et al., 1995;
Kucharczuk et al., 1999), in contrast to Myf5, where the –58/–48
kb enhancer region breaks down into discrete elements that
target different sites. Furthermore, as discussed here, crucial
elements that direct Myf5 expression in the embryo, as well as
during later stages of development, are present elsewhere in the
locus. These differences probably reflect the fact that MyoD lies
genetically downstream of Pax3 and Myf5, which govern the
entry of cells into the myogenic programme. Myf5 is therefore
the target of the signalling pathways that specify myogenic cell
fate and that differ between sites of muscle formation in the
embryo, acting through different Myf5 regulatory sequences.
Although it was not surprising that limb versus dermomyotome/
myotome expression of Myf5 should be subject to different
controls, the analysis presented here reveals the extraordinary
complexity of myogenic patterning. At least three different
regulatory circuits govern Myf5 transcription in the limb, two in
the hypoglossal cord, two in the epaxial and three in the hypaxial
dermomyotome, and probably at least three more in the
myotome. Other upstream regulatory genes, which have partially
overlapping patterns of expression, may well display a similar
complexity, such that small numbers of cells may read a
unique code specifying muscle fate. Such codes, which would
determine the myogenic body plan of a mouse, no doubt reflect
the many ways in which further cell populations were co-opted
into the muscle programme as vertebrates evolved and ever more
sophisticated muscle functions were required. Identification of
multiple Myf5 regulatory elements now makes it possible to
dissect muscle formation at any one site, both in terms of
molecular regulation and of unique cellular contributions.
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